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ABSTRACT
Purpose To evaluate Taylor dispersion analysis (TDA) as a novel
method for determination of hydrodynamic radius of therapeutic
peptides and proteins in non-stressed and stressed formulations
and to compare it with dynamic light scattering (DLS).
Methods The hydrodynamic radius of oxytocin, bovine serum
albumin,variousmonoclonalantibodies(typeIgG)andetanercept
at concentrations between 0.05 and 50 mg/ml was determined
by TDA and DLS. IgGs and etanercept were stressed (elevated
temperatures) and analyzed by TDA, DLS and HP-SEC.
Results TDA and DLS were comparable in sizing non-
stressed peptides and proteins in a concentration range of
about 0.5 to 50 mg/ml. TDA performed well even at lower
concentrations, where DLS tends to provide theoretically high
values of the Z-average radius. However, because of differ-
ences in the detection physics, DLS was more weighted
towards the detection of aggregates in stressed formulations
than TDA. Advantageously, TDA was also able to size the small
peptide oxytocin, which was not feasible by DLS.
Conclusion TDA allows the accurate determination of the
hydrodynamic radius of peptides and proteins over a wide
concentration range, with little interference from excipients
present in the sample. It is marginally less sensitive than DLS in
detecting size increase for stressed protein samples.
KEY WORDS dynamiclightscattering.hydrodynamicsize.
proteinaggregation.proteincharacterization.Taylordispersion
analysis
INTRODUCTION
The size analysis of peptides and proteins in solution, and
their associated degradation products (mainly aggregates), is
a central aspect of analytical characterization during
pharmaceutical development. Size information of peptides
and proteins can be gained by separation-based methods,
including analytical ultracentrifugation, size-exclusion chro-
matography (HP-SEC), asymmetrical flow field fraction-
ation (FFF) and SDS-PAGE (1–3). The combination of HP-
SEC and FFF with multi-angle laser light scattering
detection (4,5) and analytical ultracentrifugation allows for
the determination of both the molar mass and size without
relying on molecular weight standards. A second important
measurement principle is gaining size information by
measuring the diffusion coefficient of the molecules in
solution. The best known technique in the field of
therapeutic proteins is dynamic light scattering (DLS),
which determines the diffusion coefficient of molecules
from the intensity fluctuations of scattered light on particles
moving according to the Brownian motion (6). The
hydrodynamic radius is then derived from the diffusion
coefficient by the Stokes Einstein equation (2,6,7). DLS is a
popular technique because it is user friendly, is widely
available in pharmaceutical labs, and it enables sensitive
aggregate detection. The fact that the intensity of the
scattered light is proportional to the sixth power of the
radius results in a bias of DLS to larger sizes (6). This can
be an advantage, e.g., for the sensitive detection of small
quantities of aggregates, or a disadvantage when aiming to
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presence of larger aggregates. Many new methods of
analysis are being applied to solve the challenge of rapidly
sizing biopharmaceutical systems using small quantities. For
example, nanoparticle tracking analysis (NTA) is a novel
imaging-based technique which measures the diffusion
coefficient of individual particles by a microscope and
camera (8). Although having several advantages over DLS,
as described in detail by Filipe et al. (2010) (8), NTA is not
suitable to size peptides or protein monomers, because they
are too small for the size range of ca. 30 to 1,000 nm
covered by NTA. Thus, the opportunity for new analytical
tools to address such issues exists. In particular, methods
that facilitate rapid analysis and screening and possess high
accuracy and low sample consumption are highly desirable.
Taylor dispersion analysis (TDA) is a comparatively
unutilized method to determine the diffusion coefficients and
hydrodynamic radii of molecules. It is a fast, absolute method
based on the dispersion of a solute plug through a uniform
cylindrical tube under laminar Poiseuille flow. The method,
sometimes termed Taylor-Aris dispersion, was first described
by Taylor in 1953 (9) and developed further by Aris in 1956
(10). A plug of solute is injected into a moving solvent stream
in an open tubular column which disperses by a combination
of radial diffusion and cross-sectional velocity. So far, TDA
has mainly been employed for nanoparticles (11), polymers
(12–14) and small molecules (15,16). The reported use of
TDA for protein characterization is rare. In 1994, Bello et al.
sized the proteins ovalbumin and hemoglobin, but the
emphasis of their work was to report the major advance of
the use of small bore glass capillaries, radii≤50 μm, which
enabled the reduction of analysis time and sample consump-
tion (17). More recently published, another rare example of a
peer-reviewed article involving a protein, is a study on the
interaction of the drug propranolol with serum proteins (18).
Applications of TDA for the characterization of therapeutic
proteins in complex formulations with typically used exci-
pients have so far not been described in the literature.
In this paper, we present our evaluation of TDA for the
determination of the hydrodynamic radius of therapeutic
peptides and proteins in non-stressed and stressed formu-
lations compared to DLS. The newly commercially
available instrument for protein sizing (TDA200) utilizes
pixilated UV area imaging to improve the quality of data
collection, allowing TDA the potential to routinely measure
the hydrodynamic radius of therapeutic proteins and
peptides. The detector monitors broadening of a band of
a therapeutic protein or small molecule solution injected
into a stream of buffer solution and driven through a fused-
silica capillary using a capillary electrophoresis type
autosampler. The band is imaged at two windows, the first
on entry to and the second on exit from a loop in the
capillary. Band broadening due to Taylor dispersion is
calculated from absorbance versus time data using the peak
centre times at the first and second window, t1 and t2,
respectively, and the corresponding standard deviations, τ1
and τ2 (band broadening), using Eq. 1:
Rh ¼
4kbT t2
2   t2
1

phr2 t2   t1 ðÞ
ð1Þ
where Rh is hydrodynamic radius, kb is the Boltzman
constant, T is the temperature, η is the viscosity, and r is
the radius of capillary.
Given the interest in the pathways to protein aggregation
and analysis thereof (19), the need for analytical methods for
aggregates and subvisible particles and for evaluating their
performance is high (20). Our comparative evaluation is
timely since new analytical tools suggested to be used for
protein aggregation analysis still lack comparison to more
established methods (19). Another recent commentary strongly
supports the need for further work to assess the performance
and limitations of methods to assess protein aggregates (21).
The authors suggested that potential inaccurate quantitation
and sizing of protein aggregates by size exclusion chromatog-
raphy necessitate an essential need to use orthogonal
analytical methods to assure protein product quality.
Within the context of methods to assess protein
aggregation, the aim of our study was to evaluate the
performance of Taylor dispersion analysis (TDA) as a novel
method to determine the hydrodynamic radius of thera-
peutic proteins and peptides and their aggregates. We
report the most extensive evaluation so far of TDA
pertinent to the area of therapeutic proteins. Notably,
oxytocin, bovine serum albumin, several monoclonal anti-
bodies and etanercept are used as models, including
stressed and un-stressed formulated products. The results
obtained by TDA were compared to those of dynamic light
scattering (DLS), which has been so far the standard
technique for those applications in the pharmaceutical
field. The influence of protein concentration, the presence
of excipients, e.g. sugars, and protein aggregation on the
measurement results were factors to be investigated using
not only model proteins, but also formulated commercial
proteins. Capabilities, advantages and limitations of Taylor
dispersion analysis compared to DLS were identified and
are discussed within the manuscript. Of particular interest
was the probing of the relative ability of TDA to indicate
formulated product change after thermal stress.
MATERIALS AND METHODS
Materials
The commercial protein products Enbrel®50 mg,
Humira®40 mg and MabThera®100 mg were obtained from
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humanized IgG type 1 was used as a model protein (molar mass
150 kDa, isoelectric point ~8–9). Oxytocin and BSA were
purchased from Sigma (Sigma Aldrich, Zwijndrecht, The
Netherlands). All other substances used for preparation of
buffers and mobile phase were standard analytical grades.
Enbrel®50 mg (50 mg/ml etanercept, 10 mg/ml
sucrose, 5.8 mg/ml NaCl, 5.3 mg/ml arginine*HCl and
3.9 mg/ml Na2HPO4*2H20 pH 6.3) and Humira®40 mg
(50 mg/ml adalimumab, 2 mg/ml NaCl, 1.52 mg/ml
Na2HPO4*2H20, 0.3 mg/ml sodium citrate, 1.3 mg/ml
citric acid monohydrate, 12.0 mg/ml mannitol and
1.0 mg/ml polysorbate 80 pH 5.2) were analyzed at
different concentrations between 50 and 0.05 mg/ml. The
formulations were diluted either with only buffer (3.9 mg/
ml Na2HPO4*2H20 pH 6.3 for Enbrel®50 mg/ml and
1.52 mg/ml Na2HPO4*2H20, 0.3 mg/ml sodium citrate,
1.3 mg/ml citric acid monohydrate, pH 5.2 for
Humira®40 mg) or the placebo buffer including all
excipients. Mabthera®100 mg (10 mg/ml rituximab,
9 mg/ml NaCl, 7.3 mg/ml sodium citrate dehydrate and
0.7 mg/ml polysorbate 80, pH 6.5) was used at a
concentration of 10 mg/ml and the humanized IgG1
(1.0 mg/ml IgG, 100 mM phosphate, pH 7.2) at 1 mg/
ml. Oxytocin (50 mM phosphate, pH 4.5) was used in
concentrations between 40 and 0.05 mg/ml and BSA (PBS,
pH 7.2) between 50 and 0.05 mg/ml.
To induce aggregation, the commercial preparations
and the humanized IgG1 were subjected to 10 min thermal
stress using 1.5-ml reaction caps and a thermomixer
(Eppendorf, Germany). Enbrel®50 mg was stressed at 65
and 70°C, Humira®40 mg and Mabthera®100 mg at 60
and 65°C and the model IgG at 75 and 80°C.
Taylor Dispersion Analysis
TDA was performed on a TDA200 HT nano-sizing sytem
(Paraytec Ltd., York, UK). Samples (56 nl) were injected
into fused silica capillary under a continuous flow of buffer
(2 mm/s) using a CE injection system (PrinCE, Prince
technologies B.V., Netherlands). The corresponding for-
mulation buffer was used as running buffer. The detector
head is placed inside the CE at a controlled temperature of
25°C. The total capillary length, with ID:OD dimensions of
75:360 μm, was 143.3 cm with length to first window being
46 cm and length between windows 48.5 cm. The capillary
was cleaned between samples using a sodium hydroxide
wash (1 M). UV detection wavelength used was 214 nm.
Dynamic Light Scattering
Dynamic light scattering (DLS) was performed on a Zetasizer
Nano (Malvern, Herrenberg Germany). Five hundred μlo f
the formulations were analyzed in plastic cuvettes at 25°C
using the automatic mode for identifying the best number
of subruns and measurement time (n=3). The z-average
radius (zaverage) and polydispersity index (PDI) were
calculated from the correlation function using the
Dispersion Technology Software version 6.01 (Malvern,
Herrenberg, Germany).
Size Exclusion Chromatography (HP-SEC)
The non-stressed and stressed samples of Enbrel®50 mg,
Humira®40 mg, Mabthera®100 mg, and IgG were
analyzed by HP-SEC, using a TSKgel4000SWXL column
(Tosoh Biosep, Stuttgart, Germany) on an isocratic HPLC
system with a Waters 515 pump, a Waters 717 plus
autosampler, a Waters 474 fluorescence detector (Waters,
Milford Massachusetts, USA) and a Shimadzu SPD UV/
Vis detector (Shimadzu, Tokyo, Japan) at a flow rate of
0.5 ml/min. For the standard IgG formulations of 1.0 mg/
ml, 50 μl sample was injected. The higher concentrated
products were diluted to a concentration of 5 mg/ml using
the particular formulation buffer, and 10 μl were injected.
The mobile phase was composed of 50 mM sodium
phosphate, 150 mM arginine and 0.025% NaN3, pH 6.5.
To quantify aggregation in the IgG formulations, UV
absorption at 280 nm was used.
Statistical Analysis
Statistical analysis was performed by a one-way ANOVA
with a post-test (Tukey) using α=0.05 (95% confidence
interval) using GraphPad Prism (Version 5.02). Within the
statistical analysis, the data (radii from TDA and DLS) for
the stressed formulations were compared to the data of the
non-stressed formulation as a control.
RESULTS AND DISCUSSION
Analysis of Peptides and Proteins Varying in Size
and Concentration
No previous work has explored the use of TDA in its new
format to determine the hydrodynamic radius of an
extensive range of proteins and peptides differing in size
(Table I) over a wide concentration range and in complex
formulations containing various excipients. Oxytocin, BSA,
etanercept and adalimumab formulated at concentrations
between 0.05 and 50 mg/ml were analyzed by TDA and
DLS, with the resulting average hydrodynamic radius rh
(TDA), as well as the z-average radius rzave (DLS) and
average main peak radius rmain peak (DLS) shown in Fig. 1.
In comparing the relative strengths and weaknesses of the
2304 Hawe, Hulse, Jiskoot and Forbestwo methods, it is clear that TDA was able to provide
consistent hydrodynamic radii for the smaller sized BSA
and oxytocin at their lowest concentrations of 0.05 mg/ml.
Both DLS and TDA were successful in sizing the larger
sized antibody adalimumab at a low concentration of
0.05 mg/ml. For etanercept under the same conditions,
neither technique was ideal for sizing purposes.
Considering each of the systems in more detail, for
oxytocin the rh ranged from 0.9 to 1.1 nm when measured
by TDA over all concentrations (Fig. 1a), which is slightly
higher than the estimated hydrodynamic radius of about
0.8 nm (22). DLS proved to be less suitable for the analysis
of oxytocin. Because of the small size of oxytocin and
particularly at low concentrations, DLS analysis was
influenced by the non-protein material in the formulation,
e.g., small amounts of dust. Therefore, too high rzave values
were measured (6.9–130 nm), in particular at the lower
peptide concentrations. However, within the size distribu-
tion by intensity plots from DLS (data not shown), a peak at
about 0.9 to 1 nm representing oxytocin could be identified
for the concentration range of 1 to 40 mg/ml.
In the concentration range from 0.5 to 10 mg/ml, TDA and
DLS resulted in similar results for the hydrodynamic radius of
BSAof3.8to4.3nm(Fig.1b), which is in good agreement with
the theoretical size of 3.3 to 4.3 nm (23). At 50 mg/ml, TDA
resulted in a higher rh of 4.6 nm, whereas rzave and rmain peak in
DLS were found at 3.4 nm. At the lowest concentration of
0.05 mg/ml, rzave and rmain peak in DLS produced inconsis-
tently higher radii values than theory (8.4 nm and 5.3 nm).
For etanercept, a hydrodynamic radius between 7.0 and
8.3 nm was measured by TDA and DLS in the concentra-
tion range from 0.5 to 50 mg/ml (Fig. 1c), which is in
agreement with the theoretical value of 7.1 nm (22). For the
formulation of etanercept at 0.05 mg/ml, TDA obtained a
value rh of 4.9 nm, much lower than theoretically expected.
For this sample and conditions, it would appear the TDA
was operating at the limit of its detection. The rzave (DLS)
was unexpectedly high (41.6 nm) for 0.05 mg/ml etaner-
Fig. 1 Radius from DLS (Zaverage
radius, radius main peak) and
Taylor dispersion analysis for oxy-
tocin (a), BSA (b), etanercept (c)
and adalimumab (d). The theo-
retical hydrodynamic radii (com-
pare Table 1) are shown as light
grey areas. The results are shown
as average ± standard deviation of
n=3 (DLS) and n=5 (TDA)
individual measurements.
Table 1 Peptides and Proteins Included into the Study
Molar
mass
[kDa]
Literature values
hydrodynamic
radius [nm]
Oxytocin 1.007 ~0.8 nm (30)
a
BSA 66.8 3.3–4.3 nm (23)
3.7 nm (31)
Monoclonal antibodies: model IgG1,
adalimumab, rituximab
~150 5–6n m( 24–27)
Etanercept ~150 7.1 nm (22)
aradius estimated by Stokes-Einstein from diffusion coefficient of D=
4.34*10
−6 cm
2 s
−1 as described in (30)
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the influence of sucrose and other excipients at low protein
concentration (discussed further later).
A hydrodynamic radius of about 5.6–5.9 nm was
obtained by TDA and DLS for the concentration range
from 0.5 to 5 mg/ml for adalimumab (Fig. 1d), which is the
typical size for monomeric IgG (24–27). The slightly larger
radius (7.5–8.3 nm) for the concentrated 50 mg/ml sample
can be explained by reversible self-association, which is
often observed for monoclonal antibody formulations at
high concentrations (28). Again, the rzave determined for
0.05 mg/ml adalimumab was too high (27.7 nm), whereas
rh (TDA) and rmain peak (DLS) were still accurate.
In the concentration range from 0.5 to 50 mg/ml,
TDA and DLS were comparable to correctly determine
the size of BSA, etanercept and adalimumab in the
tested formulations. However, for the lowest concentra-
tions of 0.05 mg/ml, TDA proved to be superior over
DLS. The same behavior was identified for sizing of the
small peptide oxytocin. When measuring formulations of
low oxytocin concentrations, especially the rzave values in
DLS were far too high. TDA was capable of correctly
determining the correct size of oxytocin and the proteins
at low concentrations.
Fig. 2 Comparison of radius from TDA with Zaverage radius from DLS (a,
zoom as b), and the radius of the main peak from DLS (c) for the different
peptides and proteins measured at concentrations between 0.05 and
50 mg/ml. The results are shown as average ± standard deviation of n=3
(DLS) and n=5 (TDA) individual measurements.
Fig. 3 Radius (Zaverage radius, radius main peak) and polydispersity index
(PDI) from DLS and Taylor dispersion analysis for etanercept (a) and
adalimumab (b) diluted with formulation placebo. The results are shown
as average ± standard deviation of n=3 (DLS) and n=5 (TDA) individual
measurements.
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(rzave or rmain peak) against the rh (TDA), as shown in Fig. 2.
For this comparison of TDA with DLS, additional
measurements of rituximab, a model IgG, as well as
etanercept and adalimumab diluted in buffer, were includ-
ed. With the exception of the small peptide oxytocin
findings and practically all formulations at 0.05 mg/ml,
rzave (DLS) and rh (TDA) offered comparable results
(Fig. 2a,b). The rmain peak (DLS) and rh (TDA) were in
good agreement for all analyzed conditions (Fig. 2c).
Influence of Excipients on the Analysis
The influence of excipients on protein characterization is
an important issue, in particular as most therapeutic
proteins are applied in complex formulations. DLS eval-
uates the scattering of not just the solute of interest in
solution. As the above results confirm, with decrease in
concentration and decrease in size of the substance of
interest, DLS data can become more and more dominated
by the scattering interference from excipients present in the
formulations. Sugars and surfactants are often used as
stabilizing excipients in therapeutic protein formulations.
From previous studies for sugar solutions, e.g. sucrose, DLS
typically measures two peaks corresponding to radii of
about 0.5 nm and 100–200 nm (29). The reason for the size
of 100–200 nm is not yet fully understood. To elucidate if
TDA is also influenced by sugars, the etanercept formula-
tion, which contains 1% (w/v) sucrose, was analyzed at
etanercept concentrations between 0.05 and 50 mg/ml
(Fig. 3a). For the protein-free placebo, DLS resulted in an
rzave of 288 nm, a main peak at about 200 nm and a second
peak <1 nm. In TDA, only a rh of 0.5 nm was measured for
the sucrose-containing placebo, whereas the larger size of
200 nm was not detected. Sucrose also disturbed the DLS
measurements at the low etanercept concentration of
0.05 mg/ml, where a too high rzave was measured. At
higher protein concentrations above 0.5 mg/ml, the protein
signal dominates, and the presence of sucrose no longer
affects the rzave.
Surfactants are a second class of excipients that can disturb
DLS measurements, when used above the critical micelle
concentration. This is also the case for the adalimumab
placebo, which contains 0.1% polysorbate 80. Here, a rzave of
about 12 nm was determined by DLS, corresponding to the
polysorbate micelles (Fig. 3b). No rh could be resolved for the
formulation placebo by TDA, as the formulation buffer was
also used as a running buffer for the system.
The experiments showed that excipients like sugars and
surfactants can disturb the size analysis of proteins by DLS,
particularly for formulations with low protein concentra-
tions. TDA has more selectivity, on the other hand, and its
results were not affected to the same extent by the presence
of excipients.
Fig. 4 Results for DLS (rZave,r main
peak) and TDA (rh) for non-stressed
and aggregated formulations of
etanercept (a), adalimumab (b),
rituximab (c) and the model IgG
(d). *marks rh from TDA, #
Zaverage values from DLS, which
are significantly higher for the
stressed than for the non-stressed
formulation (p<0.05). The results
are shown as average ± standard
deviation of n=3 (DLS) and n=5
(TDA) individual measurements.
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TDA and DLS have the advantage that they can be used in
batch mode over a range of concentration without the need
for prior separation of components and without the need
for internal standards. The ability to combine stress testing
of protein formulations and rapidly detect any aggregation
tendency is an important part of the biopharmaceutical
development process. In this section of the work, we wished
to see if TDA was able to detect change in the average size
of stressed protein samples in a similar manner to DLS.
Both techniques were benchmarked using HP-SEC to
prove the formation of soluble aggregates. One advantage
of TDA over DLS would be its lower injection sample size
(previously optimized at 60 nl). TDA and DLS were
compared for their ability to detect aggregation in heat-
stressed formulations of etanercept, adalimumab, rituximab
and a model IgG (Fig. 4), as well as in etanercept samples
during a one-week accelerated stability study at 50°C (Fig. 5).
Heat stress induced the formation of soluble and non-
soluble aggregates within the formulations, as shown by
HP-SEC (Table II). In general, rzave and rmain peak (DLS)
increased to a greater extent than rh (TDA) for the
aggregated formulations (Fig. 4). This is mainly obvious
for adalimumab stressed at 65°C (Fig. 4b) and the model
IgG stressed at 80°C (Fig. 4d), which contained about 60%
soluble and non-soluble aggregates as measure by HP-SEC
(Table II). The rzave (DLS) increased from 5.7 nm (adali-
mumab) and 7.5 nm (IgG) to about 22 nm, whereas the rh
(TDA) changed from 4.6 to 6.9 nm (adalimumab) and from
6.5 to 7.5 nm (IgG) after stressing. For formulations that
mainly contained small soluble aggregates, the difference
between rzave (DLS) and rh (TDA) was less pronounced.
Whilst the absolute values of the average radii of the
samples reported by TDA and DLS may have differed
markedly on occasion, it is noteworthy that TDA was able
to identify that all four tested proteins showed significant
increase in size after undergoing the more aggressive stress
test. After exposure of the four protein formulations to the
less aggressive stress conditions, TDA results showed
significant increase in size for three of the four formulations,
whereas DLS showed all four to be significant. On
inspection of the HP-SEC data, this equates to TDA being
able to statistically significantly differentiate between a
sample of rituximab containing 99.4% monomer and one
containing 98.9% monomer but not able to discriminate
between a sample of adalimumab containing 99.3%
Fig. 5 Results for DLS (rZave) and TDA (rh) for etanercept subjected to a
1-week stability study at 50°C. *marks rh from TDA, # Zaverage values from
DLS, which are significantly higher for the stressed than for the non-stressed
formulation (p<0.05). The results are shown as average ± standard
deviation of n=3 (DLS) and n=5 (TDA) individual measurements.
Table II Size Analysis of Protein Samples by HP-SEC Quantified from UV Detection at 280 nm
Monomer [%] Dimer [%] HMW [%] Fragments [%] Recovery [%] Soluble aggregates +
non-recovered fraction [%]
Etanercept, NS 93.0 1.3 0.0 5.6 100.0 7.0
Etanerecept, 10 min 65°C 88.9 3.5 2.0 5.6 96.6 14.1
Etanerecept, 10 min 70°C 81.3 6.0 7.4 5.3 95.8 22.1
Adalimumab, NS 99.3 0.4 0.0 0.3 100.0 0.7
Adalimumab, 10 min 60°C 96.8 1.0 1.8 0.3 101.6 1.7
Adalimumab, 10 min 65°C 58.3 1.8 39.5 0.3 69.6 59.4
IgG, NS 99.1 0.0 0.0 0.9 100.0 0.9
IgG, 10 min 75°C 95.4 3.0 0.0 1.6 94.8 9.6
IgG, 10 min 80°C 45.0 8.0 44.3 2.7 87.2 60.8
Rituximab, NS 99.4 0.6 0.0 0.0 100.0 0.6
Rituximab, 10 min 60°C 98.9 0.7 0.4 0.0 100.5 0.6
Rituximab, 10 min 65°C 97.3 1.0 1.7 0.0 98.5 4.2
2308 Hawe, Hulse, Jiskoot and Forbesmonomer and one containing 96.8%. Possible contributory
factors for this difference may include the fact that the
samples were diluted for the HP-SEC analysis, whereas the
TDA and DLS samples were run without dilution.
Stress studies can form part of the drug development process
but would generally use lower temperatures than that employed
above. A comparison of the ability of TDA and DLS to identify
size changes after a longer isothermal temperature hold was
undertaken. During a one-week stability study of etanercept
performed at 50°C,a comparable observation tothose obtained
in the previous paragraph was made: the rzave (DLS) increased
to a higher level, i.e. from 6.7 nm to 20.6 nm after 7 days at
50°C, than the rh (TDA), which increased from 7.0 to 7.5 nm.
However, for both DLS and TDA the increases in rzave (DLS)
and rh (TDA) were found to be significant at day 3 of the
stability study.
The differences between DLS and TDA in their apparent
sensitivity to detect aggregation can be explained by the
different underlying measurement principles of the two
techniques. DLS is biased to larger sizes, because the intensity
of the scattered light is proportional to the sixth power of the
radius (6). In particular, larger aggregates will contribute
more to the overall scattering intensity, and the rzave is shifted
to larger sizes. In TDA, the diffusion coefficient is derived
from the band broadening measured by UV absorbance. For
a molar concentration-based detector system, it can be
assumed that monomeric and aggregated protein molecules
are detected equally (neglecting the contribution of light
scattering to the optical density at this point) and thus
averaging of the hydrodynamic radii of mixtures is a number
average (13). The inference is that TDA is more weighted
and suited to studies where the focus is protein-protein
interactions and DLS will more readily identify the larger
sized aggregates that their scattering by intensity produces.
CONCLUSIONS
This work has explored the use of TDA in its new format
linked to a pixilated area detector and compared it with DLS
to determine the hydrodynamic radius of an extensive range
ofpeptide and protein sizesin therapeuticformulationsover a
wideconcentration rangeand afterstress testing.Ourfindings
suggest that DLS and TDA have some applicationsof overlap
but that their different physical basis for the determination of
size gives rise to different strengths for the sizing of
biopharmaceuticals and their aggregates. For relatively pure
unstressed protein formulations (BSA, etancercept and mono-
clonal antibodies), TDA and DLS resulted in comparable
results for the hydrodynamic radius in the concentration
range from 0.5 to 50 mg/ml. Lower protein concentrations
(0.05mg/ml),aswellasthesmallpeptide oxytocin,could only
be sized correctly by TDA, whereas DLS resulted in much
larger values for the radius than theoretically expected.
Another advantage of TDA is that it can be selectively tuned
to detect the protein at low concentration and obviate the
strong contributory factors that some excipients can make to
DLS results. When focusing on the detection of aggregation
after stress testing, both DLS and TDA identified significant
size change for three protein systems after stressing. TDA
compared to DLS was less sensitive in a fourth case. An
explanation lies in the fact that the underlying principle of
DLS is weighted to the detection of larger particles, and as a
consequence also explains the differences in the absolute
values obtained for the two methods.
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